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Abstract
 Sequestration and cytoadherence of Background: Plasmodium falciparum
-infected erythrocytes (IE) to microvascular endothelium alters endothelial
barrier function and plays a role in the pathogenesis of severe malaria.
Binding of IE is mediated by   erythrocyte membrane protein 1P. falciparum
(PfEMP1) and the PfEMP1 variants that binds to endothelial protein C
receptor (EPCR) have, in particular, been associated with the dysregulation
of the coagulation/inflammation pathways in endothelial cells. This has
prompted speculation about the role of protease-activated receptor-1
(PAR1) activation and signalling in causing endothelial activation and loss
of barrier function in cerebral malaria.
We used a co-culture of primary human brain microvascularMethods: 
endothelial cells (HBMEC) with   material, recombinantP. falciparum
PfEMP1 or lysates from IE, and measured barrier function by trans
endothelial electrical resistance (TEER).  A selection of PAR1 inhibitors was
tested for their ability to reverse the  and thrombin inducedP. falciparum 
decrease in barrier function.
 An initial screen in the presence of recombinant PfEMP1 identifiedResults:
a few inhibitors that were able to reduce the rapid thrombin-induced barrier
disruption even when activated protein C (aPC) was unable to do so.
However, in the IE lysate co-culture system we identified a mechanism that
slowly reduces barrier function and which is insensitive to PAR1 inhibitors.
 The selected PAR1 inhibitors were able to reverse theConclusions:
disruption of barrier function by thrombin but did not reverse the IE lysate
induced disruption of barrier function, implicating a different
PAR1-independent mechanism.  These findings have implications for the
design of adjunct therapies to reduce brain swelling in cerebral malaria.
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Introduction
The pathology of cerebral malaria (CM) is not fully understood 
but is associated with sequestration of P. falciparum-infected 
erythrocyctes (IE) and involves interactions between IE and 
host endothelial cells (EC) as well as host inflammation (for 
a review see (Wassmer & Grau, 2017)). In a clinical study in 
Malawi, brain swelling was found to be strongly associated 
with fatal outcome in CM (Seydel et al., 2015), which has 
subsequently been confirmed by studies in India (Mohanty 
et al., 2017). The aetiology of this swelling is probably multi- 
factorial, involving cytopathic and vasogenic mechanisms 
(e.g. local and systemic inflammation; endothelial cell death; IE 
and erythrocyte accumulation). Multiple lines of work indicate 
involvement of the protein C (PC)–protease-activated receptor-1 
(PAR1) axis and the consequences of the loss or inactivation 
of endothelial protein C receptor (EPCR) (for a review 
see (Mohan Rao et al., 2014)) (Kessler et al., 2017). PAR1 is a 
seven-transmembrane G protein-coupled receptor and is the 
prototypical thrombin receptor. It contains its own tethered 
ligand and exhibits biased antagonism. Cleavage events at two 
different sites lead to opposing effects: when cleaved at amino 
acid R41 by thrombin, PAR1 is pro-inflammatory and barrier 
disrupting whereas non-canonical cleavage of PAR1 at amino 
acid R46 by activated PC (aPC) has a barrier stabilising and 
anti-inflammatory effect, significantly reducing the inflamma-
tory and barrier disruptive effect of thrombin on endothelial cells. 
Non-canonical cleavage of PAR1 by aPC is dependent on aPC 
binding to the active site of EPCR (Figure 1). This dysregula-
tion of the coagulation system does not often result in clinically 
evident thrombosis or bleeding in children and some research-
ers in this field have stressed the distinction between cytopathic 
and coagulant effects in this pathway (Mosnier et al., 2007). How-
ever, laboratory measurements of coagulation factors do show 
coagulation activation that is associated with fatal outcome in cer-
ebral malaria (CM) (Moxon et al., 2015).
Two mechanisms for the action of cytoadherence on coagulation/ 
inflammation dysregulation have been proposed (Figure 1). 
The direct binding of the P. falciparum variant surface protein 
P. falciparum erythrocyte membrane protein 1 (PfEMP1) to 
EPCR blocks the conversion of PC to aPC, affecting the ability 
of this host control system to control PAR1 cleavage by 
thrombin and altering the PAR1 signalling pathway (Avril 
et al., 2019; Gillrie et al., 2015; Kessler et al., 2017; Mosnier 
& Lavstsen, 2016; Sampath et al., 2015). This mechanism is 
dependent on the presence of EPCR-binding parasite variants, 
and these PfEMP1 types are strongly associated with severe 
malaria (Mkumbaye et al., 2017; Storm et al., 2019). However, 
the same effect can also be achieved through the reduction 
of expression of EPCR on the endothelial surface, which is 
thought to be expressed at lower levels in the brain microvascu-
lature. We (Moxon et al., 2013) have shown that this does occur 
and is associated with CM, and while linked to IE sequestration, 
this appears to be due to receptor shedding rather than steric 
inhibition and does not require cytoadherence via EPCR 
(Moxon et al., 2013). Either mechanism would disrupt EPCR 
function and its capacity to form a complex with aPC and 
modify PAR1 signalling; thus leading to an unmodified effect of 
Figure 1. Schematic diagram of the proposed mechanisms of endothelial dysregulation via Plasmodium falciparum cytoadherence. 
Under normal circumstances, the presence of endothelial protein C receptor (EPCR)-activated protein C (aPC) on the endothelial surface is 
able to modulate the protease-activated receptor 1 (PAR1) response (by cleavage of R46) to thrombin along a cytoprotective pathway. In the 
presence of IE, the binding site for aPC can be occupied by P. falciparum erythrocyte membrane protein 1 (PfEMP1) or EPCR expression can 
be reduced, both limiting the availability of EPCR-aPC and resulting in cytopathic responses due to unmodified thrombin cleavage (R41) of 
PAR1. P. falciparum-infected erythrocytes (IE) are also able to release soluble factors that can influence endothelial integrity directly.
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thrombin with pro-inflammatory changes and loss of EC barrier 
function. Because the dysfunction of EPCR is at the level of 
the receptor, these cannot be mitigated through the addition 
of aPC (Figure 2A).
Our hypothesis is that, through both of these mechanisms, 
the Thrombin-PAR1 coagulation/inflammation axis plays a 
significant role in barrier loss in CM, and that adjunct treat-
ments targeting this might alleviate mortality or post-CM 
neurological sequelae in CM. Since the activation of PC may be 
prevented by either of these mechanisms of EPCR disruption 
(steric inhibition or receptor cleavage) it is important to identify 
treatments that could be barrier stabilising to EPCR abroga-
tion by either mechanism. We therefore investigated a range 
of PAR1 antagonists that are able to directly inhibit thrombin 
cleavage of the PAR1 extracellular domain without affecting 
other thrombin-dependent pathways. We tested their ability in 
preventing loss of barrier function in human endothelial cells in 
response to treatment with parasite material.
Methods
Culture of endothelial cells and Plasmodium falciparum
The human umbilical vein endothelial cell line EA.hy926 
(ATCC) was cultured in DMEM medium supplemented with 10% 
Figure 2. Measuring effect of protease-activated receptor 1 (PAR1) inhibitors on endothelial barrier function of EA.hy926 cells using 
trans endothelial electrical resistance. (A) Cell Index traces for thrombin induced decrease in barrier function in EA.hy926 cells. Cell index 
was normalised at the time point immediately prior to the addition of 2 nM thrombin, indicated by the black triangle, and medium (black 
line) was set as baseline. The decrease in normalised cell index by thrombin (red) was set at 100% and the effect of 57 nM aPC (blue), 
25 nM recombinant P. falciparum erythrocyte membrane protein 1 (rPfEMP1) (bright green) and 57 nM activated protein C (aPC) and 25 nM 
rPfEMP1 combined (dark green) on thrombin induced decrease in barrier function was determined. (B) The effect of inhibitors on thrombin 
induced decrease in barrier function. Inhibitors (concentrations in Table 1) were tested in the presence of 57 nM aPC and 25 nM rPfEMP1. The 
inhibitors in light brown do not have an effect, the inhibitors in light green have and intermediate effect and the inhibitors in purple reverse the 
effect of thrombin. (C) Graph of the data depicted in B with corresponding colours. Thrombin induced decrease in barrier function was set as 
100% (red) and shown are the mean ± SD of 3 independent experiments for the 10 inhibitors. *denotes a P-value <0.05.
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foetal calf serum. Primary human brain microvascular endothe-
lial cells (HBMEC, Cell Systems) were cultured in Endothelial 
Cell Growth Medium 2 containing 2% foetal calf serum, 5 ng/ml 
epidermal growth factor, 10 ng/ml basic fibroblast growth factor, 
20 ng/ml insulin-like growth factor, 0.5 ng/ml vascular 
endothelial growth factor 165, 1 µg/ml ascorbic acid, 0.2 µg/ml 
hydrocortisone and 22.5 µg/ml heparin (EGM2, Promocell). The 
Plasmodium falciparum IT4 lab strains IT4var16 (ItG), IT4var14 
(A4) and IT4var37 (4E12) were cultured according to our stand-
ard laboratory methods (Wu et al., 2018) in complete RPMI 
medium (RPMI 1640 with 25 mM HEPES, 11 mM glucose, 
2 mM glutamine, 0.2% NaHCO3, 25 mg/l gentamicin and 
10% Human Serum, pH 7.4) in normal group O red blood 
cells (RBC) at 3% haematocrit.
rPfEMP1 preparation and PAR1 antagonists
Recombinant EPCR-binding PfEMP1 (rPfEMP1) was pro-
duced as previously described (Turner et al., 2015). In short, 
HIS-tagged cysteine-rich interdomain region domain α1 
(CIDRα1) protein derived from the IT4var20 PfEMP1 sequence 
was produced in the baculo-virus expression system, purified 
by nickel affinity chromatography and validated for binding to 
EPCR in ELISA. PAR1 antagonists, supplied by Eisai Co. Ltd. 
(Japan), and listed in Table 1, or commercially sourced from 
Sigma (Varopaxar), were dissolved at 10 mM in DMSO and stored 
in aliquots at -20°C.
Preparation of parasite lysates
Lysates of RBC and mid-trophozoite stage IE were prepared 
by freeze-thawing three times a suspension of 1 % haematocrit 
or a suspension of 50% parasitaemia at 1% haematocrit, respec-
tively, in EGM2-min medium (EGM2 without hydrocortisone 
and heparin). Enrichment of the IE by gelatine flotation was 
used to obtain 50% parasitaemia.
Trans endothelial electrical resistance (TEER) analysis
Barrier function was measured by TEER with the iCELLi-
gence™ system (ACEA Biosciences). EA.hy926 cells and 
HBMEC (up to passage 9) were seeded in 8-well E plates (L8) 
and TEER was recorded at specific time intervals and expressed 
as cell index. For the initial inhibitor screen, EAhy926 cells were 
grown overnight and when confluent, the culture medium was 
exchanged for serum- free DMEM medium and combinations 
of 25 nM rPfEMP1, 57 nM aPC or PAR1 inhibitors (see Table 1 
for concentrations) or vehicle were added 2 hours prior to treat-
ment with 2 nM thrombin (see Figure 2 for details, n=3). For 
subsequent experiments with HBMEC, the overnight culture 
medium was first replaced with EGM2 medium and then with 
EGM2-min medium 2 hours prior to the addition of lysates 
in the absence or presence of selected PAR1 inhibitors (n=5). 
After ~20 hours, the additional effect of 2 nM thrombin was 
determined (n=2). Control experiments were performed with 
medium or inhibitor only. The cell index of medium only was 
set as baseline to correct for non-specific fluctuations of cell 
index during the experiment.
The decrease in barrier function by modulators was determined 
by normalising the cell index at the time point immediately 
prior to modulator addition. The maximum decrease in normal-
ised cell index (NCI) by thrombin was determined for medium 
or lysate in the absence of inhibitor and set at 100%. The pro-
tective effect of inhibitor on the thrombin-induced disruption 
of barrier function calculated as follows:
∆NCI (thrombin + inhibitor)/∆NCI (thrombin − inhibitor) × 100.
For lysates, the normalised cell index was determined 
at 2 and 16 hours after adding the IT4var16 lysate. The 
decrease in normalised cell index was calculated and ∆NCI 
in absence of inhibitor was set at 100%. The effect of inhibi-
tor on the lysate-induced decrease in barrier function was 
calculated as follows:
∆NCI (lysate + inhibitor)/∆NCI (lysate − inhibitor) × 100.
Measuring EPCR expression on endothelial cells
The effect of IT4var14 and IT4var37 IE or IE lysate on the EPCR 
expression on HBMEC was determined after 16 - 20 hours of 
co-culture. A suspension of 50% parasitaemia at 1% haematocrit 
in EGM2-min medium was prepared and from this suspension 
lysate was also made, as described above. HBMEC were 
detached with Accutase®, washed with cold PBS/1% BSA/ 2 mM 
EDTA, labelled with phycoerythrin conjugated rat anti-human 
EPCR antibody (Biolegend, 351904), washed and stained for 
cell viability with live/dead fixable yellow stain (Invitrogen). 
EPCR expression levels of viable cells were detected by flow 
cytometry; 10 ng/ml TNF was used as a positive control, since 
it decreases EPCR expression.
Statistical analysis
Statistical significance was calculated by ANOVA with Dunnett’s 
post-test comparing the mean value (± SD) for each individual 
modulator addition (inhibitor, IE, lysate or TNF) with the mean 
value (± SD) of the condition without modulator (GraphPad 
Prism version 5). A P-value < 0.05 was deemed significant.
Table 1. Names of protease-activated 
receptor 1 inhibitors supplied by Eisai and 
concentrations used in the initial barrier 
disruption screen.
Inhibitor Compound name Conc. used
1 #91 0.1 µM
2 #33 2.5 µM
3 #01 2.0 µM
4 #62 5.0 µM
5 #04 0.1 µM
6 #39 0.5 µM
7 #38 1.0 µM
8 #11 0.1 µM
9 #96 1.0 µM
10 #90 0.5 µM
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Results
Thrombin-induced barrier disruption and the effect of 
prior treatment with either PAR1 inhibitors or aPC in the 
presence of rPfEMP1
In the initial screen we investigated whether the effect of EPCR 
binding by PfEMP1 on thrombin-mediated barrier disrup-
tion of the human umbilical vein endothelial cell line EA.hy926 
could be modified by PAR1 inhibitors. The loss of barrier func-
tion caused by the addition of thrombin was restored by the 
prior addition of aPC in the absence of rPfEMP1. However, 
aPC had no effect on preventing loss of barrier function when 
rPfEMP1 was bound to EPCR (see condition rPfEMP1- 
APC-thrombin in Figure 2) blocking aPC-mediated barrier 
strengthening. Thus, aPC might not be a useful treatment when 
EPCR-binding IE are present, such as in severe malaria. However, 
normal barrier function was obtained with the addition of 
inhibitors 1, 5 and 6 (Figure 2), suggesting that they are able to 
act to stabilise EC barrier function despite the loss of protective 
aPC-mediated PAR1 cleavage. Raw data for Figure 2, in addition 
to that for Figure 3–Figure 6, are available as Underlying 
data (Storm et al., 2020).
Developing an endothelial cell barrier model using IE 
lysates
Based on these findings we identified a subset of the Eisai 
compounds that were able to inhibit the action of thrombin on 
barrier function in the presence of rPfEMP1 and aPC. Next we 
used a co-culture system with primary HBMEC and IE. The 
work focussed on three Eisai compounds: E5555 (Atopaxar 
(Serebruany et al., 2009)), #04 (inhibitor 5) and #91 (inhibitor 1). 
E5555 was included as it has been through Phase 1 and Phase 2 
clinical testing. In addition, we used the clinically licenced 
PAR1 inhibitor Vorapaxar (brand name Zontivity (Aralez 
Pharmaceuticals)), obtained as a non-clinical compound from 
Sigma-Aldrich.
The effect of PfEMP1 ligation to EPCR on barrier function 
has been described elsewhere (Gillrie et al., 2015; Kessler 
et al., 2017), but there has been little work on the impact of EPCR 
removal from the endothelial surface during cytoadherence. To 
address this, we focussed on EPCR abrogation in our co-culture 
model and first measured the EPCR expression on HBMEC 
after overnight co-culture with IE or IE-lysate (Figure 3). 
Lysates had a more pronounced effect on EPCR expression to 
whole IE and were easier to prepare and more reproducible in 
TEER experiments. We therefore switched to a HBMEC/IE 
lysate co-culture system for subsequent experiments.
We observed that there were two ‘behaviours’ taking place in 
the TEER system (Figure 4): 
A.  A rapid response to thrombin in reducing EC barrier 
function transiently, which could be controlled under 
normal conditions using aPC (Figure 4A).
B.  A slower reduction in barrier function, activated by 
treatment with IE lysate and producing a cumulative 
effect over 30 hours (Figure 4B) that was not seen in 
control wells with RBC lysate where barrier function 
remained constant throughout the incubation period. IE 
had less of an effect on barrier function than IE lysate. 
The fluctuations in cell index in the first 2 hours are 
consistent in each experiment, probably due to the addi-
tion of cells or cellular material.
Figure 3. Endothelial protein C receptor (EPCR) expression on human brain microvascular endothelial cells after overnight culturing 
with P. falciparum-infected erythrocytes (IE) or IE lysate. EPCR expression was determined by flow cytometry after overnight culturing with 
IT4var14 or IT4var37 IE or IE lysate (n=2). EPCR expression on cells with medium only was set at 100%. Shown is mean ± SD of the combined 
IT4var14 and IT4var37 data (n=4) and the tumour necrosis factor (TNF) data (n=2) with * indicating a P-value <0.05.
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Figure 4. Measuring endothelial barrier function of human brain microvascular endothelial cells (HBMEC) using trans endothelial 
electrical resistance. (A) Cell Index traces for thrombin induced decrease in barrier function in HBMEC. Cell index was normalised at the 
time point immediately prior to the addition of 2 nM thrombin, indicated by the black triangle, and medium (black line) was set as baseline. 
Shown are the effect of 2 nM thrombin (red) on barrier function and the protection by 10 nM activated protein C (aPC) (blue) added 1 hour 
prior to thrombin. (B) Decrease in barrier function by IE, RBC and their lysates. Cell index of HBMEC was monitored and normalised at the 
time point immediately prior to the addition of cells or lysates, indicated by the black triangle at 26 hours. Medium only was set as baseline 
(black line). Normalised cell index is shown for 30 hours for red blood cells (RBC) (purple), RBC lysate (magenta), P. falciparum-infected 
erythrocytes (IE) (dark green) and IE lysate (light green). The decrease in normalised cell index was measured between 2 and 16 hours after 
addition of cells or lysate.
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Figure 5. Effect of inhibitors on thrombin-induced decrease in barrier function of human brain microvascular endothelial cells 
(HBMEC). Cell index of HBMEC without (medium) and with P. falciparum-infected erythrocyte lysate in the absence and presence of 0.3 µM 
inhibitor was monitored for ~20 hrs prior to addition of 2 nM thrombin. The cell index was normalised at the time point immediately prior to 
the addition of thrombin and medium only was set as baseline. The maximum decrease in normalised cell index by thrombin was determined 
for medium or lysate in the absence of inhibitor and set at 100%. The inhibitors reverse the effect of thrombin. Shown are the mean ± SD of 2 
independent experiments, with * indicating a P-value <0.05 compared to no inhibitor.
Figure 6. Effect of inhibitors on lysate-induced decrease in barrier function of human brain microvascular endothelial cells (HBMEC). 
Barrier function was determined in the absence and presence of 0.3 µM inhibitor. Cell index was measured and normalised at the time point 
immediately prior to the addition of P. falciparum-infected erythrocyte lysate. The normalised cell index was determined at 2 and 16 hours 
after adding the lysate. The decrease in cell index was calculated and ∆normalised cell index in absence of inhibitor was set at 100%. Shown 
is the mean ± SD of 5 independent experiments with * indicating a P-value <0.05 compared to no inhibitor.
Behaviour A was as expected and confirms that aPC rescues 
thrombin induced barrier disruption in HBMEC as seen above 
in EAhy926 cells. Behaviour B has been reported previously 
by several investigators using a range of co-culture systems 
(Tripathi et al., 2007) (Gillrie et al., 2012), with either IE or 
parasite material affecting barrier integrity. Based on these 
findings we have tested the compounds for their ability to block 
both behaviours.
Effect of PAR1 inhibitors on thrombin-induced and lysate-
induced reduction in EC barrier function
Compounds were tested for their ability to inhibit disruption 
of barrier function by thrombin and the slower effect caused by 
the IE lysate directly. All tested PAR1 inhibitors were able to 
significantly reverse thrombin-induced barrier disruption even 
in the presence of IE lysate (Figure 5). However, three of the 
four inhibitors had no significant effect on the lysate-induced 
decrease in barrier function when used at 0.3 µM (Figure 6) 
or at 0.6 µM (see Underlying data; Storm et al., 2020). Only 
E5555 significantly reverses the decrease in barrier function by 
IE lysate (-79.9 ± 16.5%, P = 0.026), albeit only by 20%. This 
still leaves a substantial EC barrier disruption by IE lysates, 
indicating that this phenomenon is independent of PAR1.
Discussion
There is considerable interest in developing adjunct thera-
pies for CM based on controlling brain swelling, following the 
MRI finding of a strong association between this phenotype 
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and death from CM (Mohanty et al., 2017; Seydel et al., 2015) 
and that brain swelling has also been associated with EPCR-
binding IE phenotype (Kessler et al., 2017). As expected, the 
PAR1 inhibitors (including Vorapaxar) were able to block the 
effect of thrombin on transient reduction in barrier function, 
including in the presence of IE lysate. However, they had no 
significant effect on the slower reduction in barrier function 
caused by the lysate itself (thrombin independent).
Blocking of the thrombin-mediated pathway with the PAR1 
antagonists might reduce brain swelling sufficiently to relieve 
mortality/morbidity in CM, but whether these types of inhibi-
tors could be used safely in children/adults with multiple ring 
haemorrhages in their brains is a concern given the potential 
bleeding risk, owing to their inhibition of PAR1 in platelets 
(https://www.rxlist.com/zontivity-side-effects-drug-center.htm). 
Further consideration of risk/benefit calculations will be required 
to answer this.
The slower effect on brain barrier function by IE lysate requires 
further investigation. Other work has implicated a role for 
β-catenin in regulating brain barrier integrity (Gallego-Delgado 
et al., 2016), showing that IE-derived soluble mediators 
are able to cause a reduction in TEER of brain endothelial 
cells over several hours. Similarly, parasite kinins were also 
shown to reduced brain endothelial cell barrier function, as 
well as enhancing IE cytoadherence (Silva et al., 2019), and 
HRP2 has been implicated in modifying barrier function (Pal 
et al., 2016). Parasite histones have also been shown to cause 
barrier disruption on lung and brain endothelial cells and to 
be released in culture by IE and in vivo in patients with CM 
(Gillrie et al., 2012) and are increased in children with CM 
and associated with blood brain barrier breakdown and brain 
swelling (Moxon et al., 2019). For histones, there are some 
therapeutic avenues that could be explored. Non-anticoagulant 
heparins prevent histone-induced lethality in bacterial sepsis 
models in vivo (Wildhagen et al., 2014) and block the toxic 
effects of plasmodial histones in vitro. A non-anticoagulant 
heparin, Sevuparin, is being used in phase II trials for malaria 
for its potential to block parasite binding (Leitgeb et al., 2017; 
Saiwaew et al., 2017). Based on the work in this paper, an 
option would be to consider a combination therapy, based on 
stopping the thrombin-mediated effect using a PAR1 inhibitor 
combined with a non-anti-coagulant heparin to mitigate the his-
tone effect. Interestingly, the two pathways are not  completely 
separate, as aPC cleaves histones to regulate histone con-
centration in the vascular compartment (Gillrie et al., 2012; 
Xu et al., 2009) and histones can reduce aPC production (Kowalska 
et al., 2014).
In summary, we have shown that PAR1 inhibitors are able to 
reduce thrombin-induced barrier disruption even when the normal 
aPC control pathway has been disabled due to direct EPCR 
engagement with PfEMP1 or by reduced EPCR expression on 
EC induced by parasite lysates. The identification of a second 
pathway for barrier disruption induced by parasite lysate 
that is insensitive to PAR1 inhibitor treatment suggests that a 
more complex approach to adjunct therapy may be needed.
Data availability
Underlying data
Figshare: Data acquired from testing the effect of PAR1 inhibi-
tors on Plasmodium falciparum-induced loss of endothelial cell 
barrier function. https://doi.org/10.6084/m9.figshare.11558889 
(Storm et al., 2020).
This project contains the following underlying data: 
•    Combined analysis data for fig 2_TEER_includes 
normalisation.csv (normalised data used to 
generate Figure 2).
•    Combined analysis data for fig5_TEER_includes 
normalisation.csv (normalised data used to 
generate Figure 5).
•    Combined analysis data for fig6_TEER_includes 
normalisation.csv (normalised data used to 
generate Figure 6).
•    Data for fig2A+B+C_TEER_EA cells+inhibitors+thromb
in_3.csv.
•    Data for fig2C_TEER_EA cells+inhibitors+thrombin_
1.csv.
•    Data for fig2C_TEER_EA cells+inhibitors+thrombin_
2.csv.
•    Data for fig3_flow cytometry HBMEC.csv.
•    Data for fig4A_TEER_aPC+thrombin_all time points 
shown.csv.
•    Data for fig4B_TEER_RBC+IE+lysate_all time points 
shown.csv.
•    Data for fig5+6_TEER_lysate+thrombin_#04-2+#91-2.csv.
•    Data for fig5+6_TEER_lysate+thrombin_#91-1.csv.
•    Data for fig5+6_TEER_lysate+thrombin_E5555-1+#04-
1.csv.
•    Data for fig5+6_TEER_lysate+thrombin_E5555-2.csv
•    Data for fig5+6_TEER_lysate+thrombin_Vorapaxar-1.csv.
•    Data for fig5+6_TEER_lysate+thrombin_Vorapaxar-2.csv.
•    Data for fig6_TEER_lysate_Vorapaxar+E5555+#04+#91-
1.csv.
•    Data for fig6_TEER_lysate_Vorapaxar+E5555+#04+#91-
2.csv.
•    Data for fig6_TEER_lysate_Vorapaxar+E5555+#04+#91-
3.csv.
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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